The American Cancer Society (ACS) estimates 60,300 new leukemia diagnosis in the U.S. this year. Sadly, roughly 24,370 will succumb to the disease. Leukemia originates in the blood stem cells as either immature myeloid stem cells (monocytes, platelets, or granulocytes, which form clots or fight bacteria and infection) or immature lymphoid stem cells (or lymphocyte B, T or NK cells, which are white blood cells that battle infection and bodily threats). These immature cells, known as blast cells, produce abnormally and excessively, forcing out protective healthy cells. Leukemia occurs in four main types, which are grouped dependant upon if they develop from lymphoid stem cells (known as lymphoblastic leukemias) or myeloid stem cells (known as myelogenous leukemias): 1. Acute lymphocytic leukemia ACS research reports approximately 5,960 new cases of acute lymphocytic leukemia (or ALL) yearly in the U.S., and roughly 1,470 annual deaths. ALL largely affects child patients (3 in 4 children with leukemia) before the age of 5-years old. However, the majority of ALL deaths occur in patients older than 50-years old due to the fact that younger patients better respond to aggressive ALL treatment, which usually includes a combination of chemotherapy, radiation therapy, stem cell transplant, and sometimes immunology.